Mechanistic insights into the mitigation of Aβ aggregation and protofibril destabilization by a D-enantiomeric decapeptide rk10.

Abstract

According to clinical studies, the development of Alzheimer's disease (AD) is linked to the abnormal aggregation of amyloid-β (Aβ) peptides into toxic soluble oligomers, protofibrils as well as mature fibrils. The most acceptable therapeutic strategy for the treatment of AD is to block the Aβ aggregation. Sun and co-workers have reported a decapeptide, D-enantiomeric RTHLVFFARK-NH2 (rk10), which acts as a potent inhibitor of Aβ aggregation and efficiently disaggregates pre-assembled Aβ fibrils. However, the inhibitory mechanism of rk10 against Aβ aggregation and disassembly of fibrils remains obscure. To investigate the inhibitory mechanism of rk10 against Aβ aggregation and disassembly of fibrils, molecular dynamics (MD) simulations have been performed in the present study. The molecular docking analysis using AutoDock Vina predicted favourable binding of rk10 with the N-terminal and central hydrophobic core (CHC) residues of Aβ42 monomer (-5.3 kcal mol-1), and with the residues of chain A of Aβ42 protofibril structure (-6.9 kcal mol-1). The MD simulations depicted higher structural stability of Aβ42 monomer in the presence of rk10. Notably, rk10 prevented the sampling of β-sheet rich structures of Aβ42 monomer by reducing the side-chain contacts between N-terminal and C-terminal residues of Aβ42 monomer. The per-residue binding free energy analysis highlighted the significant contribution of Phe19 and Glu22 of Aβ42 monomer in binding with rk10, which corroborate with the 1H NMR (nuclear magnetic resonance) spectra of Aβ42 monomer + rk10 complex that depicted a change in the chemical shifts of amide protons of Phe19 and Glu22. Further, rk10 destabilized the Aβ42 protofibril structure by lowering the number of interchain hydrogen bonds. The binding free energy analysis predicted lower binding affinity between Aβ42 protofibril chains in the presence of rk10 as compared to Aβ42 protofibril alone. The insights into the inhibitory mechanism of rk10 against Aβ aggregation and disassembly of fibrils will be beneficial for the design and development of potent anti-amyloid inhibitors.